Görgec Burak, Verpalen Inez M, Sijberden Jasper P, Abu Hilal Mohammad, Bipat Shandra, Verhoef Cornelis, Swijnenburg Rutger-Jan, Besselink Marc G, Stoker Jaap
From the Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
Cancer Center Amsterdam, Amsterdam, The Netherlands.
Ann Surg Open. 2024 Mar 18;5(1):e401. doi: 10.1097/AS9.0000000000000401. eCollection 2024 Mar.
Abdominal computed tomography (CT) is the standard imaging modality for detection and staging in patients with colorectal liver metastases (CRLM). Although liver magnetic resonance imaging (MRI) is superior to CT in detecting small lesions, guidelines are ambiguous regarding the added value of an additional liver MRI in the surgical workup of patients with CRLM. Therefore, this systematic review and meta-analysis aimed to evaluate the clinical added value of liver MRI in patients eligible for resection or ablation of CRLM based on CT.
A systematic search was performed in the PubMed, Embase, and Cochrane Library databases through June 23, 2023. Studies investigating the impact of additional MRI on local treatment plan following CT in patients with CRLM were included. Risk of bias was assessed using the QUADAS-2 tool. The pooled weighted proportions for the primary outcome were calculated using random effect meta-analysis.
Overall, 11 studies with 1440 patients were included, of whom 468 patients (32.5%) were assessed for change in local treatment plan. Contrast-enhanced liver MRI was used in 10 studies, including gadoxetic acid in 9 studies. Liver MRI with diffusion-weighted imaging was used in 8 studies. Pooling of data found a 24.12% (95% confidence interval, 15.58%-32.65%) change in the local treatment plan based on the added findings of liver MRI following CT. Sensitivity analysis including 5 studies (268 patients) focusing on monophasic portal venous CT followed by gadoxetic acid-enhanced liver MRI with diffusion-weighted imaging showed a change of local treatment plan of 17.88% (95% confidence interval, 5.14%-30.62%).
This systematic review and meta-analysis found that liver MRI changed the preinterventional local treatment plan in approximately one-fifth of patients eligible for surgical resection or ablation of CRLM based on CT. These findings suggest a clinically relevant added value of routine liver MRI in the preinterventional workup of CRLM, which should be confirmed by large prospective studies.
腹部计算机断层扫描(CT)是结直肠癌肝转移(CRLM)患者检测和分期的标准成像方式。尽管肝脏磁共振成像(MRI)在检测小病灶方面优于CT,但对于在CRLM患者手术评估中额外进行肝脏MRI的附加价值,指南并不明确。因此,本系统评价和荟萃分析旨在评估基于CT适合进行CRLM切除或消融的患者中肝脏MRI的临床附加价值。
截至2023年6月23日,在PubMed、Embase和Cochrane图书馆数据库中进行了系统检索。纳入研究CRLM患者在CT后额外MRI对局部治疗方案影响的研究。使用QUADAS - 2工具评估偏倚风险。使用随机效应荟萃分析计算主要结局的合并加权比例。
总体而言,纳入了11项研究共1440例患者,其中468例患者(32.5%)接受了局部治疗方案的改变评估。10项研究使用了对比增强肝脏MRI,其中9项研究使用了钆塞酸。8项研究使用了肝脏MRI联合弥散加权成像。数据汇总发现,基于CT后肝脏MRI的额外发现,局部治疗方案有24.12%(95%置信区间,15.58% - 32.65%)的改变。包括5项研究(268例患者)的敏感性分析聚焦于单相门静脉CT后进行钆塞酸增强肝脏MRI联合弥散加权成像,结果显示局部治疗方案改变为17.88%(95%置信区间,5.14% - 30.62%)。
本系统评价和荟萃分析发现,肝脏MRI在约五分之一基于CT适合进行CRLM手术切除或消融的患者中改变了干预前的局部治疗方案。这些发现提示常规肝脏MRI在CRLM干预前评估中具有临床相关的附加价值,这应由大型前瞻性研究予以证实。